Amarin Corporation plc (AMRN)
| Market Cap | 296.56M -3.0% |
| Revenue (ttm) | 186.23M -15.1% |
| Net Income | -27.12M |
| EPS | -1.30 |
| Shares Out | 21.12M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 51,753 |
| Open | 14.27 |
| Previous Close | 14.39 |
| Day's Range | 13.90 - 14.30 |
| 52-Week Range | 12.96 - 20.90 |
| Beta | 0.76 |
| Analysts | Strong Sell |
| Price Target | 12.50 (-10.97%) |
| Earnings Date | Oct 28, 2026 |
About AMRN
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers. It has a collaborat... [Read more]
Financial Performance
In 2025, Amarin Corporation's revenue was $213.65 million, a decrease of -6.55% compared to the previous year's $228.61 million. Losses were -$38.80 million, -52.79% less than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for AMRN stock is "Strong Sell." The 12-month stock price target is $12.5, which is a decrease of -10.97% from the latest price.
News
Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026
Presentations Expand Understanding of Treatment Adherence, Long-Term Outcomes, Lipoprotein(a), Coagulation Biomarkers, and Potential Mechanisms of Eicosapentaenoic Acid (EPA)
New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients
DUBLIN and BRIDGEWATER, N.J., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today highlighte...
New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026
DUBLIN and BRIDGEWATER, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced ...
Amarin reinstated with an Underweight at JPMorgan
JPMorgan analyst Jessica Fye reinstated coverage of Amarin (AMRN) with an Underweight rating and $13 price target The firm does not see significant downside from current levels, but believes Amarin’s…
Amarin Corporation Transcript: Transcript
Q2 2026 saw strong international growth for VASCEPA, especially in Europe via the Recordati partnership, and stable U.S. performance despite pricing pressure. Operating loss narrowed, cash flow remained positive, and restructuring drove significant cost savings.
Amarin Corporation Slides
Amarin Corporation has posted slides in relation to its latest quarterly earnings report, which was published on July 30, 2026.
Amarin Corporation Quarterly report
Amarin Corporation has published a quarterly earnings report on July 29, 2026.
Amarin Corporation Earnings release
Amarin Corporation released its earnings on July 29, 2026, summarizing the period's financial results.
Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence
Q2 2026 Results Highlight Global Volume Growth, Lower Operating Expenses and Positive Cash Flow For Full Year 2026, Company Expects Continued Growth in International Markets, Maintenance of VASCEPA's ...
Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026
DUBLIN, Ireland and BRIDGEWATER, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announce...
Amarin Corporation Transcript: Transcript
Q2 2024 revenue declined year-over-year due to U.S. generic competition, but international growth, especially in Europe and China, offset some pressure. Cost-saving initiatives improved profitability, and the company remains focused on global expansion and maintaining U.S. market leadership.
Amarin Corporation Transcript: Transcript
Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape
Clinically Validated, Increasingly Prescribed, Widely Reimbursed, and Affordable, VASCEPA Expected to Benefit from Increased Attention to Patients with Severely Elevated Triglycerides Clinically Valid...
New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia
DUBLIN and BRIDGEWATER, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) (Amarin), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, t...
Amarin Corporation Transcript: Transcript
Q1 2026 saw revenue growth, improved margins, and a second consecutive quarter of positive cash flow, driven by a new operating model and strong international momentum. Vascepa maintained U.S. leadership, while updated guidelines and restructuring supported future growth.
Amarin Corporation Slides: Corporate presentation
Amarin Corporation has posted slides in relation to its latest quarterly earnings report, which was published on April 29, 2026.
Amarin Reports 2026 First Quarter Financial Results
Total Revenue Increased Led by Higher International Sales Generated Positive Cash Flow and Reiterates Expectation for Full Year Positive Cash Flow Recently Updated Industry Guidelines Expand Global Me...
Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026
DUBLIN and BRIDGEWATER, N.J., April 15, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced that i...
Amarin highlights new recommendation for treatment of CV risk
Amarin (AMRN) celebrated the recommendation that the treatment of CV risk in patients with hypertriglyceridemia be part of a broader dyslipidemia management as discussed in the 2026 American College o...
Amarin to present data in patients at extreme cardiovascular risk
Amarin (AMRN) “announced that additional REDUCE-IT patient subgroup analysis and additional mechanistic data on potential multifactorial biologic activities will be presented at the American College o...
Amarin highlights recent data published on REDUCE-IT study
Amarin (AMRN) Corporation highlighted recently published data in the European Journal of Preventive Cardiology showing in a post hoc analysis of the REDUCE-IT study that, among statin-treated particip...
Amarin CFO says ‘well positioned’ to deliver on 2026 strategic priorities
Peter Fishman, Amarin’s (AMRN) Chief Financial Officer, said, “Our fourth quarter performance reflects our early success in optimizing the Company’s operations and creating what we believe is a more e...
Amarin issues call to action for American Heart Month
Amarin (AMRN) Corporation issued a call to action for American Heart Month emphasizing a message that cannot wait: the United States has an opportunity to significantly reduce heart attacks, strokes,…
This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease
DUBLIN and BRIDGEWATER, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today iss...
US Supreme Court to hear 'skinny label' patent fight involving Amarin
The U.S. Supreme Court agreed on Friday to hear a patent dispute involving Amarin Pharma's cardiovascular drug Vascepa that could have broad consequences for generic drug makers and so-called "skinny ...